Grace Therapeutics (GRCE) news
Recent news
Grace Therapeutics reports $10M placement
Grace Therapeutics, Inc. (Nasdaq: GRCE) recently announced a private placement financing of $15 million in upfront gross proceeds, with the potential to receive an additional $15 million through warrant exercises, for a total potential gross of up to $30 million. The financing was led by Nantahala…
AInvest Wire · Aug 5, 2026Grace Therapeutics receives FDA Type A meeting minutes regarding April 23, 2026 CRL
AInvest Wire · Jul 28, 2026GTEX for commercial and industrial investments quarterly net loss attributable $1.8 mln
Grace Therapeutics, Inc. (Nasdaq: GRCE) reported a net loss of approximately $2.3 million, or $0.14 per share, for the three months ended December 31, 2025, representing a decrease of $1.8 million compared to the net loss of $4.2 million, or $0.36 per share, for the same period in the prior year.…
AInvest Wire · Jul 16, 2026Grace Therapeutics announces 2026 fiscal year-end financial results, provides business update
Grace Therapeutics, Inc. (Nasdaq: GRCE) reported its financial results for the fiscal year ended December 31, 2025, and provided an update on its business operations. The company continues to advance its lead drug candidate, GTx-104, an intravenous formulation of nimodipine for the treatment of…
AInvest Wire · Jun 18, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.